Showing 2481-2490 of 3570 results for "".
- Biosimilar News: FDA Approves Stelara Biosimilar Wezlanahttps://practicaldermatology.com/news/biosimilar-news-fda-approves-stelara-biosimilar-wezlana/2462118/The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Stelara (ustekinumab) for psoriasis and multiple other inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc. Wezlana, like Stelar
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Lebrikizumab Update: IL-13 Blocker Performs Well in AD Inadequately Controlled With Cyclosporinehttps://practicaldermatology.com/news/lebrikizumab-update-il-13-blocker-performs-well-in-ad-inadequately-controlled-with-cyclosporine/2462070/Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately controlled with cyclosporine or for whom cyclosporine was not medically adv
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and